Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics Inc (NQ: DYN )

32.51 -0.38 (-1.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 513,494
Open 32.85
Bid (Size) 32.49 (17)
Ask (Size) 32.53 (1)
Prev. Close 32.89
Today's Range 31.97 - 33.06
52wk Range 6.400 - 35.98
Shares Outstanding 58,310,703
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+148.93%
+148.93%
1 Month
+26.74%
+26.74%
3 Month
+22.96%
+22.96%
6 Month
+181.23%
+181.23%
1 Year
+127.66%
+127.66%

More News

Read More
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Why Is Dyne Therapeutics Stock Soaring On Monday?
Via Benzinga
Tech Surge Boosts Nasdaq To Record Highs
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
Via Investor's Business Daily
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
From Dyne Therapeutics, Inc.
Via GlobeNewswire
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Dyne Therapeutics Announces CEO Transition
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Via Benzinga
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
Via Benzinga
Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
Via Benzinga
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.